Placebo News and Research

RSS

SANUWAVE Health reports financial results for the three months ended September 30, 2009

SANUWAVE Health, Inc.,, an emerging medical technology company focused on the development and commercialization of non-invasive, biological response activating devices in the regenerative medicine area, reports its achievements and financial results for the three and nine months ended September 30, 2009.

16 Nov 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse-. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

16 Nov 2009

New reversible blood thinner for angioplasty patients not superior over placebo

A new reversible blood thinner for angioplasty patients wasn't superior over placebo for its primary combined endpoint of heart attack, all-cause mortality and need for revascularization, but it reduced mortality and in-stent blood clots, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

16 Nov 2009

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Ore Pharmaceutical Holdings Inc. today reported financial results and provided an operational update for the third quarter ended September 30, 2009.

13 Nov 2009

Third quarter 2009 financial results announced by Soligenix

Soligenix, Inc., (Soligenix or the Company) (OTC Bulletin Board: SNGX), formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today its financial results for the third quarter of 2009.

13 Nov 2009

CNS Pharmaceuticals' common shares sponsored by 886 AG on the electronic trading platform Xetra

CNS PHARMACEUTICALS AG, (C35.F) a developer and marketer of patented natural nutraceutical products is pleased to announce that the Company’s common shares is sponsored by the German Securities Trading Bank 886 AG Wertpapier Handelsbank on the electronic trading platform Xetra.

13 Nov 2009

Findings on the use of Traumeel S in children with mucositis undergoing SCT presented

New research findings presented today at the Society for Integrative Oncology's (SIO) Sixth International Conference in New York show promise in assessing the efficacy and safety of complementary and alternative medicine (CAM) using traditional research methods.

13 Nov 2009

Shire announces findings from Phase 3 study data with Vyvanse

Shire plc, the global specialty biopharmaceutical company, announced findings from a post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse®. In this study, Vyvanse demonstrated significant improvement in Attention-Deficit/Hyperactivity Disorder (ADHD) symptoms as measured by the ADHD Rating Scale IV (ADHD-RS IV) and Connors' Parent Rating Scale-Revised Short (CPRS-RS) in children with ADHD aged 6 to 12 years.

13 Nov 2009

Vanderbilt University researchers study role of statins in reducing flu-related deaths

Vanderbilt University Medical Center researchers are studying statins, the class of drugs long associated with lowering cholesterol, as a way to reduce H1N1-related deaths.

13 Nov 2009

LA BioMed to participate in a national study of the effectiveness of testosterone

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) announced today that it will participate in a large national study of the effectiveness of testosterone as a treatment for anemia, cardiovascular disease, decreased vitality, impaired memory and sexual function, loss of muscle mass and other health conditions that affect older men.

13 Nov 2009

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.

13 Nov 2009

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Mithridion, Inc., a biopharmaceutical company focusing on developing drugs for serious Central Nervous System (CNS) disorders, announced today progress with its pipeline of potential oral small-molecule drugs for Alzheimer's disease (AD) and schizophrenia.

13 Nov 2009

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

Lexicon Pharmaceuticals, Inc. announced today that the company's investigational new drug, LX1031, a tryptophan hydroxylase (TPH) inhibitor, demonstrated positive results in clinically important parameters for the treatment of non-constipating irritable bowel syndrome (IBS).

13 Nov 2009

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

arGentis Pharmaceuticals, LLC today announced that it will collaborate with the University of Tennessee Health Science Center (UTHSC) and the Veterans Affairs Medical Center of Memphis (VAMC) to initiate the first human clinical evaluation of an oral altered peptide ligand (APL), ARG301, in a Phase I study of Rheumatoid Arthritis patients.

12 Nov 2009

Tobira Therapeutics presents data on TBR-652 at the European AIDS Conference

Tobira Therapeutics, a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced pharmacokinetic data and results from two double-blind, placebo-controlled studies of TBR-652 in eighty-four healthy volunteers.

12 Nov 2009

Oxytocin hormone affects behaviors, finds new study

A new study carried out at the University of Haifa has found that oxytocin, also known as the "love hormone", which affects behaviors such as trust, empathy and generosity, also affects opposite behaviors, such as jealousy and gloating.

12 Nov 2009

Some benefits from prescription drug DTCA, but significant risks remain

While the debate over prescription drug advertising persists, a new study released online in the American Journal of Public Health offers guidelines for improving drug ads in order to minimize potential harm and maximize benefits. The study reveals that while there are some benefits from prescription drug direct-to-consumer advertising (DTCA), there are significant risks that are magnified by the prominence of DTCA.

12 Nov 2009

Bend Memorial Clinic to begin Phase III lung cancer trial

The Bend Memorial Clinic is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease’s recurrence in previously treated patients. Specifically, the trial is evaluating the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

11 Nov 2009

Potential benefits of Labopharm's novel trazodone formulation published

Labopharm Inc. today announced an article has been published in the international journal of neuropsychiatric medicine, CNS Spectrums October, 2009 issue, citing the potential benefit of its novel trazodone formulation, which contains Contramid(R). Labopharm's Contramid is the clinically validated proprietary technology that controls the release of active substances from oral medications to optimize drug delivery.

11 Nov 2009

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

AVANIR Pharmaceuticals, Inc. today announced efficacy, safety and tolerability results from the 12-week open-label extension phase of the confirmatory Phase III STAR trial evaluating the investigational drug Zenvia™ (dextromethorphan/quinidine) in the treatment of patients with pseudobulbar affect (PBA).

11 Nov 2009

Placebo News and Research

SANUWAVE Health reports financial results for the three months ended September 30, 2009

Findings from post hoc analysis examining emotional lability from Phase 3 study data with Vyvanse announced

New reversible blood thinner for angioplasty patients not superior over placebo

Ore Pharmaceutical Holdings reports financial results and provides operational updates for third quarter 2009

Third quarter 2009 financial results announced by Soligenix

CNS Pharmaceuticals' common shares sponsored by 886 AG on the electronic trading platform Xetra

Findings on the use of Traumeel S in children with mucositis undergoing SCT presented

Shire announces findings from Phase 3 study data with Vyvanse

Vanderbilt University researchers study role of statins in reducing flu-related deaths

LA BioMed to participate in a national study of the effectiveness of testosterone

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

Mithridion reports progress with its potential oral small-molecule drugs for AD and schizophrenia

Positive results from Lexicon Pharmaceuticals' LX1031 Phase 2 study for IBS

arGentis Pharmaceuticals to commence human clinical evaluation of ARG301 oral altered peptide ligand

Tobira Therapeutics presents data on TBR-652 at the European AIDS Conference

Oxytocin hormone affects behaviors, finds new study

Some benefits from prescription drug DTCA, but significant risks remain

Bend Memorial Clinic to begin Phase III lung cancer trial

Potential benefits of Labopharm's novel trazodone formulation published

Avanir Pharmaceuticals unveils Star trial results for Zenvia in the treatment of PBA

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News